A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy

Nguyễn, Quang Vinh; Lym, Jae Seung; Huynh, Cong Truc; Kim, Bong Sup; Jae, Hwan Jun; Kim, Young Il; Lee, Sang Soo

doi:10.1039/c6py01141a

Cited by 30 publications

(37 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, amphiphilic copolymer was conjugated with heparin to construct non-anticoagulant heparin prodrugs loaded in thermosensitive hydrogel for anti-metastasis treatment [121] and as a GEM carrier for the treatment of pancreatic cancer [122]. Moreover, PCLA–PEG–PCLA copolymer was modified via polyaddition polymerization with sulfamethazine, acting as anionic pH-sensitive moiety, to synthesize a dual stimuli responsive polymeric system, proposed for the DOX release in liver cancer [123]. Finally, injectable pentablock copolymer hydrogels PEG–PCL–PLA–PCL–PEG, with different ratios of PCL and PLA, were proposed as single-shot sustained release of vaccines.…”

Section: Synthetic Injectable Hydrogelsmentioning

confidence: 99%

Injectable Hydrogels for Cancer Therapy over the Last Decade

et al. 2019

View full text Add to dashboard Cite

The interest in injectable hydrogels for cancer treatment has been significantly growing over the last decade, due to the availability of a wide range of starting polymer structures with tailored features and high chemical versatility. Many research groups are working on the development of highly engineered injectable delivery vehicle systems suitable for combined chemo-and radio-therapy, as well as thermal and photo-thermal ablation, with the aim of finding out effective solutions to overcome the current obstacles of conventional therapeutic protocols. Within this work, we have reviewed and discussed the most recent injectable hydrogel systems, focusing on the structure and properties of the starting polymers, which are mainly classified into natural or synthetic sources. Moreover, mapping the research landscape of the fabrication strategies, the main outcome of each system is discussed in light of possible clinical applications.

show abstract

Section: Synthetic Injectable Hydrogelsmentioning

confidence: 99%

Injectable Hydrogels for Cancer Therapy over the Last Decade

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Besides to chemical crosslinking hydrogel, physical crosslinking hydrogels with stimulus responsive phase changes were also popular design as TACE reagents. As a typical example, Nguyen et al (2016) synthesized an amphiphilic anionic PCLA-PUSSM copolymer made of poly(ethylene glycol) (PEG), poly(ε-caprolactone- co -lactide) (PCLA), and poly(urethane sulfide sulfamethazine) (PUSSM), as illustrated in Figure 5A. The PCLA-PUSSM copolymer solution remained liquid status at pH 8.5 and experienced fast phase change and solid status hydrogel formation upon pH decrease.…”

Section: Polymer Based Hydrogels As Tace Reagentsmentioning

confidence: 99%

“…(C) CT observations revealed the shrinkage of tumor size when using PCLA-PUSSM hydrogel as TACE agent. [Reproduced with permission from Nguyen et al (2016), Copyright 2016 Royal Society of Chemistry].…”

Section: Polymer Based Hydrogels As Tace Reagentsmentioning

confidence: 99%

Recent Advances on Polymeric Beads or Hydrogels as Embolization Agents for Improved Transcatheter Arterial Chemoembolization (TACE)

et al. 2019

View full text Add to dashboard Cite

Transcatheter arterial chemoembolization (TACE), aiming to block the hepatic artery for inhibiting tumor blood supply, became a popular therapy for hepatocellular carcinoma (HCC) patients. Traditional TACE formulation of anticancer drug emulsion in ethiodized oil (i.e., Lipiodol ® ) and gelatin sponge (i.e., Gelfoam ® ) had drawbacks on patient tolerance and resulted in undesired systemic toxicity, which were both significantly improved by polymeric beads, microparticles, or hydrogels by taking advantage of the elegant design of biocompatible or biodegradable polymers, especially amphiphilic polymers or polymers with both hydrophilic and hydrophobic chains, which could self-assemble into proposed microspheres or hydrogels. In this review, we aimed to summarize recent advances on polymeric embolization beads or hydrogels as TACE agents, with emphasis on their material basis of polymer architectures, which are important but have not yet been comprehensively summarized.

show abstract

“…[ 17 ] Moreover, as utilizing unevaluated excipients, the recently reported hydrogel‐based embolic reagents are not yet available in clinical practice because of the doubtable biocompatibility. [ 18–24 ] Therefore, the development of the ideal thermosensitive hydrogel embolic reagent for TACE treatment is still needed but challenging.…”

Section: Introductionmentioning

confidence: 99%

Precision Embolism: Biocompatible Temperature‐Sensitive Hydrogels as Novel Embolic Materials for Both Mainstream and Peripheral Vessels

Wang

Shen

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Complete blood blockage and low ectopic embolism risk are urgently needed for transcatheter arterial chemoembolization (TACE) treatment. However, the clinically available embolic reagents still face the huge challenges of fast recanalization and undesirable migration. In the present work, a temperature‐sensitive poloxamer 407 (F127)/hydroxymethyl cellulose (HPMC)/sodium alginate (SA)‐derived hydrogel (FHSgel) is explored as a novel embolic material in the TACE treatment. With increasing temperature, this FHSgel undergoes sensitive phase transition process, so as to block both mainstream and peripheral vessels. Meanwhile, taking advantage of the close fitness between shapeable FHSgel and vessels, the embolism time is extremely extended. Moreover, the leaked FHSgel could be diluted below the gelation concentration, thus effectively preventing from ectopic embolism. TACE treatment is further conducted for rabbit liver and kidney tumors, wherein the atrophic blood vessels and necrotic tissue demonstrate superior therapy effect. In addition, all three pharmaceutical excipients are approved by the Food and Drug Administration (FDA). In contrast with the clinical embolic reagents, the temperature‐sensitive FHSgel for the first time completely blocks both mainstream and peripheral vessels with totally biocompatible pharmaceutical excipients, and makes a breakthrough in terms of largely reducing the ectopic embolism risk, thus providing a new generation for interventional embolization.

show abstract

A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy

Abstract: After transcatheter delivery through hepatic artery, a hydrogel can be formed within tumor vasculature by the decrease of environmental pH, block the blood vessel and control the release of loaded anticancer drugs.

Cited by 30 publications

References 59 publications

Injectable Hydrogels for Cancer Therapy over the Last Decade

Injectable Hydrogels for Cancer Therapy over the Last Decade

Recent Advances on Polymeric Beads or Hydrogels as Embolization Agents for Improved Transcatheter Arterial Chemoembolization (TACE)

Precision Embolism: Biocompatible Temperature‐Sensitive Hydrogels as Novel Embolic Materials for Both Mainstream and Peripheral Vessels

Contact Info

Product

Resources

About